Physician Assistant CME Courses

Physician Assistant CME Courses

Format: Interactive Online, Online Streaming Video, PDF
Price: Free
Release Date: November 02, 2017
Expiration Date: November 02, 2019
Summary:

Multiple myeloma (MM) is a hematologic malignancy of the lymphocytes. All cases are marked by monoclonal gammopathy, and while the true cause is unknown, associated factors are thought to include: radiation, genetics, viral infections, and the human immunodeficiency virus. Helping the clinician discern the role of each of the first-line and more novel therapies, including monoclonal antibodies and proteasome, deacetylase, and 3 serine/threonine protein kinase inhibitor therapies – among others – based on the most up-to-date research merits continuing education programming in MM.

By the end of the session the participant will be able to:

  • Recall updates in the staging, prognosis, and diagnosis of MM.
  • Distinguish between the most appropriate treatment approaches to MM and apply them to practice, taking into account the following: treatment modalities and the recent clinical trial evidence supporting them.
  • Distinguish between the most appropriate treatment approaches to MM and apply them to practice, taking into account the following: evidence-based treatment guidelines, algorithms, and expert opinion.
  • Summarize the risk-benefit profiles of current and emerging therapies for the treatment of MM.
Format: Online Streaming Video, Interactive Online
Price: Free
Release Date: October 13, 2017
Expiration Date: October 13, 2019
Summary:

By the end of the session the participant will be able to:

  • Describe the epidemiology of AUD and outline current and evolving diagnostic criteria
  • Describe challenges to the successful identification of patients with AUD
  • Identify the treatment modalities currently available for management of AUD and apply them to patient cases using evidence-based medicine
  • Develop strategies for recognizing and improving therapeutic adherence in patients treated for AUD

Alcohol use disorder (AUD), referred to colloquially as alcoholism, is an integration of past terms that have include in past as alcohol dependence or abuse, and may be marked by any one of a number of different symptoms or behaviors that include physical cravings, compulsion, guilt, and frequent consumption over an extended period of time. There are about 7.9 million people in the United States who suffer from the disease, but a fraction – 2.2 million people – seek treatment for it. The number of people who are considered heavy drinkers is about double at somewhere between 15.9 and 17.6 million, and just under a quarter of Americans over age 12 reports having engaged in binge drinking at least once in the last month. Alcohol accounts for over 687,000 emergency department visits by people under age 20 per year, and AUD is estimated to cost $223.5 billion per year. Worldwide, 76.3 million people are estimated to have AUDs, and they account for an annual mortality rate of 1.8 million. AUD is largely undertreated, constituting one gap in care and justifying CME


Format: Online Streaming Video
Price: Free
Release Date: September 04, 2017
Expiration Date: September 04, 2019
Summary:
This is an online CME self-learning program.

Rheumatoid arthritis (RA) is a systemic autoimmune disorder in which joints, typically those in the hands and feet, become inflamed, swollen, painful, and stiff. Without appropriate treatment, the inflammation may become chronic and cause irreversible destruction of bone and cartilage in the affected joints as well as contribute to the development of clinically important co-morbid conditions with attendant morbidity and mortality. The National Arthritis Data Workgroup estimates that about 1.3 million U.S. adults (0.6% of the adult population) have RA. RA imposes a considerable disease burden. Patients with RA have substantially lower health-related quality of life (QOL) than the general population with lower overall scores for physical and mental health across all age groups.The RA disease burden also is associated with increased health care resource utilization. Notably, RA patients with low QOL are twice as likely to be hospitalized as RA patients with high QOL.

Some have suggested that criteria used for the past two decades are inadequate for addressing the disease burden of RA because by the time a physician detects rheumatoid nodules or radiographic erosion, the optimal time has passed for treatment initiation, representing a gap in care relating to diagnosis of disease. Another potential gap is illustrated by studies in which researchers demonstrated that a systematic, objective approach to therapy with Disease Activity Score-driven therapy yields superior outcomes to routine care.

By the end of the session the participant will be able to:

  • Describe the pathophysiology of RA such that it might inform treatment mechanisms.
  • Describe professional guideline recommendations’ approaches to the diagnosis and treatment of RA and, where applicable, apply them to patient cases
  • Identify the currently available and emerging pharmacotherapeutic treatments for management of RA and apply them to patient cases using evidence-based medicine.
  • Evaluate a treatment plan for a specific patient with RA to optimize safety and efficacy, suggesting modifications for improvement, including the management of comorbidities.
  • Describe the challenges and barriers to care associated with treating patients with RA.

Share This